中国中医科学院 中医临床基础医学研究所,北京 100700
王雅星,博士,从事中药上市后再评价研究,E-mail:452111538@qq.com
谢雁鸣,首席研究员,博士生导师,从事中药上市后研究与评价,E-mail:ktzu2018@163.com
收稿:2023-10-07,
网络出版:2024-01-12,
纸质出版:2024-03-20
移动端阅览
王雅星,苏鑫鑫,黄艳丽等.一清胶囊治疗热毒证的药品临床综合评价[J].中国实验方剂学杂志,2024,30(06):126-133.
WANG Yaxing,SU Xinxin,HUANG Yanli,et al.Comprehensive Clinical Evaluation of Yiqing Capsules in Treating Heat-toxin Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(06):126-133.
王雅星,苏鑫鑫,黄艳丽等.一清胶囊治疗热毒证的药品临床综合评价[J].中国实验方剂学杂志,2024,30(06):126-133. DOI: 10.13422/j.cnki.syfjx.20241094.
WANG Yaxing,SU Xinxin,HUANG Yanli,et al.Comprehensive Clinical Evaluation of Yiqing Capsules in Treating Heat-toxin Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(06):126-133. DOI: 10.13422/j.cnki.syfjx.20241094.
目的
2
通过系统梳理一清胶囊治疗热毒证咽炎、扁桃体炎、牙龈炎、口腔溃疡的现有研究,明确其内在优势价值及治疗特点,为国家卫生医药决策相关部门提供参考,同时为临床和基础的研究提供基础和线索。
方法
2
采用定性和定量相结合的评价方法,基于多准则决策(MCDA)模型,应用CSC v2.0软件从多方面对一清胶囊进行临床综合评价。
结果
2
一清胶囊自发呈报系统(SRS)监测数据中严重不良反应包括瘙痒、皮疹、腹泻等,均好转或痊愈,无加重或转院治疗。文献数据显示临床不良反应主要表现为腹痛、腹泻等,急性毒性和长期毒性均显示安全性较好,一清胶囊安全性评为B级;Meta分析结果显示,一清胶囊单用或者联合治疗伴有热毒证咽炎、扁桃体炎、牙龈炎、口腔溃疡在症候改善情况、疾病主症消失率、口疮复发率等方面优于牛黄解毒胶囊或西药治疗,药理药效学显示一清胶囊具有抗菌、抗病毒、抗炎等作用,有效性评为B级;从卫生体系角度出发,采用决策树模型,根据增量效应水平分析,以1倍人均国内生产总值(GDP)作为阈值条件下,一清胶囊在治疗热毒证牙龈炎以牙龈炎疼痛消失率为指标,与牛黄解毒胶囊组采用增量成本效果比为0.39元/%,相比更具有经济性优势,且成本可接受,经济性评为B级;一清胶囊既能清气分热,又能泻血分火毒,为清下并行,以下为清的代表方剂,适用于热毒证,同时结合企业产业服务体系和企业创新性,综合得创新性评为B级;本品一般不需要个体化治疗方案,供应贮运方便,政策宣传和药品信息规范,医护、患者都易操作;中成药信息齐全,符合国家标准,适宜性评为A级;一清胶囊价格水平低,可获得性及可负担性较好,可及性评为A级;一清胶囊的原经方“三黄泻心汤”源于古医书,且真实世界研究较丰富,中医药特色评为C级。
结论
2
综合“6+1”维度,采用CSC v2.0软件计算得出,一清胶囊的临床价值评价为B类,建议可按程序有条件转化为基本临床用药管理的相关政策结果。
Objective
2
To systematically review the studies about Yiqing Capsules in the treatment of pharyngitis, tonsillitis, gingivitis, and oral ulcers with heat-toxin syndrome and clarify the advantages and therapeutic characteristics of Yiqing capsules, thus providing reference for the decision-making by relevant departments and clues for the clinical and basic research.
Method
2
The multi-criteria decision analysis (MCDA) model and CSC v2.0 were employed to comprehensively evaluate Yiqing capsules from multiple aspects.
Result
2
The serious adverse reactions in the spontaneous reporting system (SRS) monitoring data of Yiqing capsules included pruritus, rash, an ddiarrhea, all of which were relieved or cured, without aggravation or interhospital transfer for treatment. Literature data showed that the main clinical adverse reactions were abdominal pain, diarrhea, etc. Both acute toxicity and long-term toxicity tests showed good safety, and thus the safety of Yiqing capsules was rated as grade B. The results of Meta-analysis showed that Yiqing capsules used alone or in combination with other medicines outperformed Niuhuang Jiedu capsules or Western medicine in the treatment of pharyngitis, tonsillitis, gingivitis, and oral ulcers with heat toxin in terms of symptom alleviation, disappearance rate of main symptoms, and recurrence rate of aphtha. Pharmacological and pharmacodynamic studies showed that Yiqing capsules had antimicrobial, antiviral, and anti-inflammatory effects, with the effectiveness rated as grade B. The decision tree model was adopted to analyze the incremental cost-effectiveness ratio. With the threshold of 1 fold per capita GDP and the disappearing rate of pain in gingivitis as the indicator, Yiqing capsules had an economic advantage in the treatment of gingivitis due to heat-toxin compared with Niuhuang Jiedu capsules, and the incremental cost-effectiveness ratio was 0.39 yuan/%, which indicated acceptable cost, with the economy rated as grade B. Yiqing capsules can not only clear heat from Qi aspect but also purge blood fire, serving as the representative prescription of clearing and purging for heat-toxin syndrome. Considering the industrial service system and enterprise innovation, the comprehensive innovation of Yiqing capsules was rated as grade B. Generally, this product does not require personalized treatment plans and features convenient supply, storage, transportation, policy publicity, drug information standards, and easy operation for medical care and patients. The Chinese patent medicine information was complete and in line with national standards, and thus the suitability of Yiqing capsules was rated as grade A. With a low price and good availability and affordability, the accessibility of Yiqing capsules was rated as grade A. The Yiqing capsules prescription, Sanhuang Xiexin decoction, originated from ancient medical books, with rich real-world studies, and thus the traditional Chinese medicine characteristics of Yiqing capsules was rated as grade C.
Conclusion
2
The clinical value of Yiqing capsules was rated as grade B from the "6+1" dimensions, suggesting that it could be conditionally converted into the relevant policy results of basic clinical drug management according to the procedure.
郭榕榕 . 基于明清温病医著对热毒的证治规律研究 [D]. 银川 : 宁夏医科大学 , 2021 .
王永炎 , 纪鑫毓 , 张华敏 . 读《素问·五常政大论篇》诠释人生格局的自然化 [J]. 北京中医药大学学报 , 2021 , 44 ( 4 ): 293 - 297 .
周仲瑛 . 中医内科学 [M]. 北京 : 中国中医药出版社 , 2003 .
SIDELL D , SHAPIRO N L . Acute tonsillitis [J]. Infect Disord Drug Targets , 2012 , 12 ( 4 ): 271 - 276 .
张丽 . 急性扁桃体炎的辨证论治体会 [J]. 内蒙古中医药 , 2013 , 32 ( 20 ): 22 .
WEBER R . Pharyngitis [J]. Prim Care , 2014 , 41 ( 1 ): 91 - 98 .
TARAKJI B , GAZAL G , AL-MAWERI S A , et al . Guideline for the diagnosis and treatment of recurrent aphthous stomatitis for dental practitioners [J]. J Int Oral Health , 2015 , 7 ( 5 ): 74 - 80 .
周尚儒 , 郭玫 , 王志旺 , 等 . 大黄治疗痤疮的研究进展 [J]. 甘肃科技 , 2020 , 36 ( 2 ): 156 - 160 .
刘旭海 . 大黄药理作用及临床应用研究进展 [J]. 山东医学高等专科学校学报 , 2007 , 29 ( 3 ): 229 - 231 .
刘昌云 , 李书雅 , 燕陶然 , 等 . 黄芩在痤疮中的应用概述 [J]. 中国民间疗法 , 2020 , 28 ( 1 ): 104 - 105 .
龚盛昭 , 揭育科 , 袁水明 . 黄芩苷在功能性化妆品中的应用研究 [J]. 日用化学工业 , 2003 , 33 ( 3 ): 200 - 203 .
李娜 , 王一飞 , 张明 . 中医药治疗痤疮的作用机理研究进展 [J]. 光明中医 , 2016 , 31 ( 24 ): 3690 - 3694 .
中国药品综合评价指南项目组 . 中国药品综合评价指南参考大纲(第二版) [J]. 药品评价 , 2015 ( 8 ): 6 .
国家卫生健康委办公厅 . 药品临床综合评价管理指南(2021年版试行) [EB/OL]( 2021-07-28 ).[ 2021-12-21 ]. https://www.cn-healthcare.com/article/20210728/content-557909.html https://www.cn-healthcare.com/article/20210728/content-557909.html .
ANGELIS A , LINCH M , MONTIBELLER G , et al . Multiple criteria decision analysis for HTA across four EU member states:Piloting the advance value framework [J]. Soc Sci Med , 2020 , 246 : 112595 .
SHEA B J , GRIMSHAW J M , WELLS G A , et al . Development of AMSTAR:A measurement tool to assess the methodological quality of systematic reviews [J]. BMC Med Res Methodol , 2007 , 7 : 10 .
HIGGINS J P , ALTMAN D G , GøTZSCHE P C , et al . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials [J]. BMJ , 2011 , 343 : d5928 .
GUYATT G , OXMAN A D , SULTAN S , et al . GRADE guidelines:11.Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes [J]. J Clin Epidemiol , 2013 , 66 ( 2 ): 151 - 157 .
王燕 . 中西药联用治疗复发性阿弗他溃疡效果探讨 [J]. 河南医学研究 , 2016 , 25 ( 7 ): 1246 - 1247 .
彭骊苏 , 李敏 , 周红梅 , 等 . 一清胶囊治疗(热毒证)复发性阿弗他溃疡的多中心临床研究 [J]. 实用口腔医学杂志 , 2012 , 28 ( 6 ): 766 - 770 .
冯琛琛 , 陈文 , 桂湧 , 等 . 一清胶囊治疗边缘性牙龈炎随机、双盲、多中心临床试验 [J]. 实用口腔医学杂志 , 2013 , 29 ( 4 ): 560 - 564 .
丁红 , 阎博华 , 田理 , 等 . 一清胶囊治疗热毒证的多中心、随机、双盲、对照试验 [J]. 辽宁中医杂志 , 2011 , 38 ( 8 ): 1486 - 1490 .
魏瑞丽 , 王志飞 , 马晓昌 , 等 . 稳心颗粒治疗心律失常(气阴两虚证)的临床综合评价 [J]. 中国中药杂志 , 2021 , 46 ( 23 ): 6068 - 6077 .
徐雄良 , 刘浪 , 刘小均 , 等 . 一清胶囊抗炎作用实验研究 [J]. 西北药学杂志 , 2016 , 31 ( 4 ): 392 - 394 .
耿洪娇 , 谢雁鸣 , 王志飞 . 脑心通胶囊治疗气虚血瘀证脑梗死及冠心病心绞痛的临床综合评价 [J]. 中国中药杂志 , 2021 , 46 ( 23 ): 6087 - 6095 .
冯琛琛 , 陈文 , 桂湧 , 等 . 一清胶囊治疗边缘性牙龈炎随机、双盲、多中心临床试验 [J]. 实用口腔医学杂志 , 2013 , 29 ( 4 ): 560 - 564 .
雷超 , 谭畅 , 张强 , 等 . 痫愈胶囊治疗癫痫风痰闭阻证的临床综合评价 [J]. 中国实验方剂学杂志 , 2023 , 29 ( 3 ): 117 - 126 .
崔鑫 , 韩晟 , 高景华 , 等 . 金天格胶囊治疗骨质疏松症的临床综合评价 [J]. 中国实验方剂学杂志 , 2023 , 29 ( 11 ): 151 - 159 .
张强 , 王志飞 , 谢雁鸣 , 等 . 中成药临床综合评价报告规范 [J]. 中国中药杂志 , 2021 , 46 ( 23 ): 6062 - 6067 .
0
浏览量
192
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
